Johnson & Johnson announced that the US Food and Drug Administration (FDA) has approved the Tecnis PureSee intraocular lens (IOL), an extended depth of focus (EDOF) IOL intended for use in cataract surgery. The company said the lens will become available in the United States later this year.

The Tecnis PureSee lens is designed to provide distance and intermediate vision with some near vision while maintaining contrast sensitivity comparable to an aspheric monofocal intraocular lens. According to the company, it is the first FDA-approved EDOF lens in the United States without a warning regarding reduced contrast sensitivity.

EDOF lenses aim to broaden the range of functional vision while minimizing photic phenomena often associated with multifocal optics. In clinical data cited by the company, 97% of patients reported no very bothersome visual disturbances such as halos or glare following implantation.

The Tecnis PureSee lens expands the company’s cataract surgery portfolio, which includes the Eyhance and Odyssey IOLs. The lens has already been introduced in several international markets, with nearly half a million eyes implanted worldwide, according to the company. OM